NCT07511569Not yet recruiting
Prospective Exploratory Study of a Multiomic Blood Biomarker Panel to Predict Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Source: ClinicalTrials.gov · Last updated 13 Apr 2026
Brief summary (registry, in English)
The goal of this prospective, multicenter, observational cohort study with longitudinal blood sampling and standardized neurological evaluation over 6 months is to identify biomarkers to predict the overall occurrence of chronic chemotherapy-induced peripheral neuropathy (CIPN, any grade), in each of two treatment subgroups (taxanes and oxaliplatin). It involves integration of clinical data and plasma multiomic biomarkers (proteomic + metabolomic panel) analyzed via supervised machine learning to identify predictive features of CIPN.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 192 (estimated)
- First submitted
- 30 Mar 2026
- Start date
- 4 Jan 2027
- Primary completion date
- 4 Jan 2029
- Lead sponsor
- Centre Hospitalier de Bligny
- Diseases
- Childhood cancers
- NCT number
- NCT07511569
What you commit to
- Study type: Observational
- Planned participants: 192
- From 4 Jan 2027 to the primary completion date, 4 Jan 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have already received neurotoxic cancer treatment including those in clinical trials
- Patients receiving two of the study molecules simultaneously (only one study molecule is permitted, including in combination chemotherapy but that does not include another neurotoxic molecule)
- Patients receiving immunotherapy
Other illness
- Patients with type 1 or type 2 diabetes (for more than 10 years for type 2 diabetes)
Other
- Patients already suffering from neuropathy or chronic neurogenic pain
Who the study is looking for
- Patients who have received detailed information about the study and have signed, with the investigator, a consent form to participate in the study
- Patients being treated for cancer at any stage of the disease and scheduled to receive chemotherapy including one (and only one) of the following molecules: paclitaxel, docetaxel, or oxaliplatin, for a planned duration of 9 weeks or more
- Age \> 18 years
- Life expectancy \> 3 months
- Patient affiliated with or entitled to social security
Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.